LCS
SMMT icon

Levin Capital Strategies’s Summit Therapeutics SMMT Stock Holding History

Levin Capital Strategies’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$673K Buy
46,176
+8,500
+23% +$151K 0.05% 157
2026
Q1 		$714K Hold
37,676
– – 0.05% 131
2025
Q4 		$659K Buy
37,676
+1,000
+3% +$18.8K 0.06% 114
2025
Q3 		$758K Buy
36,676
+500
+1% +$12.1K 0.07% 106
2025
Q2 		$770K Hold
36,176
– – 0.07% 104
2025
Q1 		$698K Hold
36,176
– – 0.07% 97
2024
Q4 		$646K Hold
36,176
– – 0.06% 110
2024
Q3 		$792K Sell
36,176
-3,000
-8% -$42K 0.08% 102
2024
Q2 		$306K Hold
39,176
– – 0.03% 165
2024
Q1 		$162K Hold
39,176
– – 0.02% 205
2023
Q4 		$102K Hold
39,176
– – 0.01% 230
2023
Q3 		$73.3K Hold
39,176
– – 0.01% 247
2023
Q2 		$98.3K Hold
39,176
– – 0.01% 245
2023
Q1 		$68.6K Hold
39,176
– – 0.01% 223
2022
Q4 		$166K Hold
39,176
– – 0.02% 194
2022
Q3 		$47K Hold
39,176
– – 0.01% 219
2022
Q2 		$39K Sell
39,176
-5,000
-11% -$7.01K ﹤0.01% 249
2022
Q1 		$108K Hold
44,176
– – 0.01% 274
2021
Q4 		$119K Buy
44,176
+414
+0.9% +$1.99K 0.01% 296
2021
Q3 		$219K Buy
43,762
+5,000
+13% +$35.9K 0.02% 269
2021
Q2 		$289K Buy
38,762
+5,262
+16% +$34.5K 0.03% 235
2021
Q1 		$197K Buy
+33,500
New +$216K 0.02% 257

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Levin Capital Strategies's SMMT Position: Q2 2026 in Review

Levin Capital Strategies increased its Summit Therapeutics (SMMT) stake by 23% in Q2 2026, buying an estimated $151K and bringing the position to 46,176 shares worth $673K. The position accounts for 0.05% of the portfolio, ranked #157.

Levin Capital Strategies first reported a position in SMMT in Q1 2021 and has held it in 22 quarters since. The position peaked at $792K in Q3 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Levin Capital Strategies held 46,176 shares of Summit Therapeutics worth $673K as of Q2 2026.
  • Levin Capital Strategies bought 8,500 Summit Therapeutics shares in Q2 2026, an estimated $151K.
  • Summit Therapeutics made up 0.05% of Levin Capital Strategies's portfolio in Q2 2026, its #157 holding.
  • Levin Capital Strategies first reported a position in Summit Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Levin Capital Strategies's Summit Therapeutics position peaked at $792K in Q3 2024.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Levin Capital Strategies's 13F filing for Q2 2026, filed 31 Jul 2026.